ArticleBMC cancer2026
Trends in mortality among patients with malignant neoplasm of kidney in the United States, 1999-2023: a retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to identify trends in malignant neoplasm of kidney -related mortality in the United States from 1999 to 2023, and examine variations in these trends by sex, race, and region.
methodsAge-adjusted mortality rates (AAMRs) and crude death rates (CDRs) per 100,000 by sex, race/ethnicity, age group, and geographic regions were used. AAMRs and CDRs were analyzed using the Joinpoint Regression Program to calculate annual percentage changes (APCs) and average APCs (AAPCs).
resultsBetween 1999 and 2023, male individuals exhibited higher mortality rates due to malignant neoplasms of the kidney compared to their female counterparts. When analyzed by race and ethnicity, Black patients recorded the highest age-adjusted mortality rate (AAMR) throughout the study period, reaching 6.38 per 100,000 individuals in 1999. Moreover, AAMRs were consistently elevated in rural regions compared to urban settings. Regarding age demographics, individuals aged 85 and older experienced the highest overall crude mortality rate of 31.05 per 100,000 individuals in 1999. In contrast, the lowest rate was observed in the 25–34 age group, at 0.13 per 100,000 individuals during the same year. Additionally, significant regional disparities in mortality rates were observed across the Midwest, Northeast, and Western regions.
conclusionSignificant sociodemographic disparities exist in the mortality trends of malignant neoplasm of kidney in the United States. These findings highlight the need for targeted interventions and further research to address these disparities and improve outcomes for all populations affected by malignant neoplasm of kidney.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.